Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder of which the principal pathological characteristic is the loss of dopamine (DA) neurons of the substantia nigra pars compacta (SNc) (Hassler, 1938). Parkinsonian signs appear when dopaminergic neuronal death exceeds a critical threshold: 70–80% of striatal nerve terminals and 50–60% of SNc pericarya (Bernheimer et al., 1973). The nature of the etiology of the process underlying clinical deterioration remains unknown, but PD is characterized by its progressiveness (Hoehn and Yahr, 1967). Although cell death processes and compensatory mechanisms, responsible for the gradual appearance and worsening of clinical signs, are better understood through the identification of genetic mutations responsible for familial cases of PD (Dawson and Dawson, 2003b) and the use of neurotoxin-based animal models (Berg et al., 2001, Blum et al., 2001, Dawson and Dawson, 2003a, Giasson and Lee, 2001), our understanding of PD progression remains close to zero.
Indeed, most experimental approaches have ignored the progressive nature of PD and have not taken into account the possibility that cell death mechanisms may vary accordingly to the extent of degeneration. Until recently, it has proved difficult to ascertain both the nature of such a sequence of events and its relationship with any subsequent plastic response of the SN. In the absence of animal models that replicate the progressive degenerative processes and the difficulty of longitudinal studies in man, it has been impossible to investigate such a question of paramount importance. Recently, an animal model of PD, which is able to address these issues, has been developed (Bezard et al., 2003). In this model, repeated administration of low doses of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to the nonhuman primate (Macaca fascicularis) initiates a process of neurodegeneration reminiscent of that seen in PD (Bezard et al., 2001c, Bezard et al., 2003). The novelty of the model accrues from the fact that, during the first 13–15 days of the protocol, despite significant dopaminergic loss, symptoms, are not apparent. During this period, several mechanisms compensate for the increasing loss of DA, suppressing the appearance of symptoms (Bezard et al., 1999, Bezard et al., 2001a, Bezard et al., 2001b, Bezard et al., 2001c). The model is thus extremely attractive for defining neural mechanisms, and potential biomarkers, that relate to the progression of PD.
High-density oligonucleotide arrays offer the opportunity to survey the transcriptional profiles of large numbers of genes and allow complex biology especially as it relates to disease processes, making possible the unraveling of the basis of PD progression (Marvanova et al., 2003). In this model-driven study, in contrast to hypothesis-driven experiments, we have taken advantage of our progressive nonhuman primate paradigm to monitor transcriptional fluctuations in the SN using human Affymetrix microarray technology, previously shown to display statistically satisfactory human and macaca cross-hybridization properties (Marvanova et al., 2003).
Section snippets
Animals
Experiments were conducted on twenty-one female cynomolgus monkeys (M. fascicularis, CAS, Beijing, PR China; mean age = 3.0 ± 0.2 years; mean weight = 2.8 ± 0.2 kg). Animals were housed in individual primate cages under controlled conditions of humidity (50 ± 5%), temperature (24 ± 1°C) and light (12h light/12h dark cycles, time lights on 8:00 am), food and water were available ad libitum and animal care was supervised by veterinarians skilled in the healthcare and maintenance of nonhuman
Changes in motor behavior
Changes in motor behavior were fully comparable to those previously reported with this administration protocol (Bezard et al., 2001c). Monkeys at day 6 (D6; n = 5) and day 12 (D12; n = 5) did not exhibit parkinsonian motor symptoms (parkinsonian score of 0 for all animals at both time points; P > 0.5 compared to both control and saline groups). Both the D6 and D12 groups were thus asymptomatic. Monkeys in the day 25 (D25; n = 5) group exhibited parkinsonian motor abnormalities as reflected by
Discussion
The present work relates to the relationship between the transcription changes in the SN and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of PD. Five clusters can be described as five temporal profiles that are likely to represent activation/deactivation of mechanisms of different nature. We briefly speculate about (i) the existence of yet unknown compensatory mechanisms is unraveled, (ii) the putative triggering of a developmental program in the mature
References (35)
- et al.
Slit proteins prevent midline crossing and determine the dorsoventral position of major axonal pathways in the mammalian forebrain
Neuron
(2002) - et al.
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
J. Neurol. Sci.
(1973) - et al.
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey
Brain Res.
(1997) - et al.
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys
Neurobiol. Dis.
(2001) - et al.
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
Trends Neurosci.
(2003) - et al.
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease
Prog. Neurobiol.
(2001) - et al.
Parkin and the molecular pathways of Parkinson's disease
Neuron
(2001) - et al.
An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin
Cell
(2001) - et al.
A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses pael receptor-induced cell death
J. Biol. Chem.
(2003) - et al.
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Neurodegeneration
(1995)
Genes involved in hereditary ataxias
Trends Neurosci.
A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy
NeuroImage
Neuroprotective strategies for Parkinson's disease: conceptual limits of clinical trials and animal models
Trends Pharmacol. Sci.
Molecular mechanisms underlying midbrain dopamine neuron development and function
Eur. J. Pharmacol.
Compensations after lesions of central dopaminergic neurons: some clinical and basic implications
Trends Neurosci.
Brain iron pathways and their relevance to Parkinson's disease
J. Neurochem.
Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms
Eur. J. Neurosci.
Cited by (27)
Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease
2015, Free Radical Biology and MedicineSex differences in Parkinson's disease
2014, Frontiers in NeuroendocrinologyCurrent status and future directions of gene expression profiling in Parkinson's disease
2012, Neurobiology of DiseaseCitation Excerpt :For example, one recent experiment used SNDA neuron expression profiling to search for novel genetic loci for vulnerability to PD and reported an association, although two subsequent studies failed to replicate the finding (Elstner et al., 2009; Guella et al., 2010; Vilarino-Guell et al., 2010). So far, the majority of studies have been performed on the midbrain and striatum in postmortem samples from PD patients and animal models of parkinsonism (Bassilana et al., 2005; Bossers et al., 2009; Duke et al., 2007; Grunblatt et al., 2004; Hauser et al., 2005; Miller et al., 2004, 2006; Moran et al., 2006; Papapetropoulos et al., 2006; Sutherland et al., 2009; Zhang et al., 2005). More recently, studies have targeted enriched populations of dopamine neurons (as opposed to tissue pieces) and have begun to explore extra-nigral neurons and peripheral tissues (Cantuti-Castelvetri et al., 2007; Meurers et al., 2009; Mutez et al., 2010; Scherzer et al., 2007; Simunovic et al., 2009, 2010; Stamper et al., 2008; Yacoubian et al., 2008).
Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease
2010, Brain ResearchCitation Excerpt :The increased expression of the complement components C1S and C4B was specifically detected in the MPTP SN. Contrary to our study, dysregulation of neuroinflammatory genes was not detected in the other MPTP monkey study data of day 25 (Bassilana et al., 2005). UPS pathway genes exhibited moderate concordance across studies although significantly expressed genes in each study were varied.
Genes regulated in MPTP-treated macaques and human Parkinson's disease suggest a common signature in prefrontal cortex
2010, Neurobiology of DiseaseCitation Excerpt :The references to every individual, phenotype, gender, age and post-mortem delay are listed in Table 1. Protocols were already published in details elsewhere as substantia nigra data have been published (Bassilana et al., 2005; Marvanova et al., 2003). Briefly, five animals were treated daily for 15 days with saline and were killed after 25 days, i.e. they received the same number of injections as those that received the MPTP treatment (and followed the same treatment as those used to induce parkinsonism), and were termed saline group.